These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24495769)

  • 61. Hematopoietic stem cell transplantation conditioning with use of rituximab in EBV related lymphoproliferative disorders.
    Shamriz O; Vilk SR; Wolf DG; Ta-Shma A; Averbuch D; Weintraub M; Stepensky P
    Clin Immunol; 2014 Apr; 151(2):79-83. PubMed ID: 24584040
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Correlation between phenotypic heterogeneity and gene mutational characteristics in familial hemophagocytic lymphohistiocytosis (FHL).
    Ueda I; Ishii E; Morimoto A; Ohga S; Sako M; Imashuku S
    Pediatr Blood Cancer; 2006 Apr; 46(4):482-8. PubMed ID: 16365863
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Novel Munc13-4 mutations in children and young adult patients with haemophagocytic lymphohistiocytosis.
    Santoro A; Cannella S; Bossi G; Gallo F; Trizzino A; Pende D; Dieli F; Bruno G; Stinchcombe JC; Micalizzi C; De Fusco C; Danesino C; Moretta L; Notarangelo LD; Griffiths GM; Aricò M
    J Med Genet; 2006 Dec; 43(12):953-60. PubMed ID: 16825436
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Origin of macrophages involved in the development of allogeneic hematopoietic stem cell transplantation-associated hemophagocytic syndrome: observations on a patient with juvenile myelomonocytic leukemia.
    Ishida H; Yoshida H; Yoshihara T; Ito M; Morimoto A
    Bone Marrow Transplant; 2007 Oct; 40(7):701-3. PubMed ID: 17646843
    [No Abstract]   [Full Text] [Related]  

  • 65. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment.
    Chandrakasan S; Filipovich AH
    J Pediatr; 2013 Nov; 163(5):1253-9. PubMed ID: 23953723
    [No Abstract]   [Full Text] [Related]  

  • 66. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
    Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
    Peters C; Schrappe M; von Stackelberg A; Schrauder A; Bader P; Ebell W; Lang P; Sykora KW; Schrum J; Kremens B; Ehlert K; Albert MH; Meisel R; Matthes-Martin S; Gungor T; Holter W; Strahm B; Gruhn B; Schulz A; Woessmann W; Poetschger U; Zimmermann M; Klingebiel T
    J Clin Oncol; 2015 Apr; 33(11):1265-74. PubMed ID: 25753432
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico.
    Llano OG; Perez JC; Rodriguez OC; Guerra CM; Aguirre HG; Garza JL; Rodriguez-Romo L; Almaguer DG
    Pediatr Hematol Oncol; 2008; 25(1):39-47. PubMed ID: 18231953
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Myeloablative unrelated cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: comparison with other graft sources from related and unrelated donors.
    Konuma T; Kato S; Ooi J; Oiwa-Monna M; Tojo A; Takahashi S
    Ann Hematol; 2015 Feb; 94(2):289-96. PubMed ID: 25178518
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sirolimus-containing graft-versus-host disease prophylaxis in patients with lymphoma.
    Mehta J
    J Clin Oncol; 2009 Oct; 27(28):e138; author reply e139-40. PubMed ID: 19720890
    [No Abstract]   [Full Text] [Related]  

  • 71. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.
    Raiola AM; Dominietto A; di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Varaldo R; Ghiso A; Gobbi M; Carella AM; Signori A; Galaverna F; Bacigalupo A
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1573-9. PubMed ID: 24910379
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Familial hemophagocytic lymphohistiocytosis in the neonate.
    Whaley BF
    Adv Neonatal Care; 2011 Apr; 11(2):101-7. PubMed ID: 21730897
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Reduced intensity conditioning and hematopoietic stem cell transplantation in pediatric nonmalignant disease: a new therapeutic paradigm.
    Abikoff CM; Cairo MS
    J Pediatr; 2014 May; 164(5):952-953.e2. PubMed ID: 24742647
    [No Abstract]   [Full Text] [Related]  

  • 74. Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
    Abdel-Azim H; Mahadeo KM; Zhao Q; Khazal S; Kohn DB; Crooks GM; Shah AJ; Kapoor N
    Am J Hematol; 2015 Nov; 90(11):1021-6. PubMed ID: 26242764
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Gastric antral vascular ectasia in 2-yr-old girl undergoing unrelated cord blood stem cell transplantation.
    Kuroiwa Y; Suzuki N; Mizue N; Hori T; Endo T; Yoshida Y; Tsutsumi H
    Pediatr Transplant; 2005 Dec; 9(6):788-91. PubMed ID: 16269052
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 77. In vivo T-cell depletion using alemtuzumab in family and unrelated donor transplantation for pediatric non-malignant disease achieves engraftment with low incidence of graft vs. host disease.
    Saif MA; Borrill R; Bigger BW; Lee H; Logan A; Poulton K; Hughes S; Turner AJ; Bonney DK; Wynn RF
    Pediatr Transplant; 2015 Mar; 19(2):211-8. PubMed ID: 25546609
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Late relapse of primary hemophagocytic lymphohistiocytosis after hematopoietic stem cell transplantation: a consequence of low-level chimerism from a carrier donor?
    Verrinder AE; Marsden JLS; Slatter MA; McDonald L; Bacon CM; Majo J; Gennery AR
    Immunol Res; 2019 Jun; 67(2-3):261-264. PubMed ID: 31264179
    [No Abstract]   [Full Text] [Related]  

  • 79. Toxoplasmosis-Associated Hemophagocytic Lymphohistiocytosis in Allogeneic Transplantation.
    Cutini I; Gozzini A; Nozzoli C; Boncompagni R; Innocenti C; Fani A; Saccardi R
    J Clin Immunol; 2021 May; 41(4):843-846. PubMed ID: 33515363
    [No Abstract]   [Full Text] [Related]  

  • 80. [Multicenter report of nonmyeloablative allogeneic stem cell transplantation for hematologic diseases].
    Ai HS; Huang XJ; Qiao ZH; Wang JM; Chen BA; Bai H; Shi BF; Liang YM; Sun WJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Aug; 30(8):505-8. PubMed ID: 19954634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.